New life-extending treatment for rare forms of advanced gastro-oesophageal cancer recommended by NICE

NICE

24 November 2022 - Around 3,000 people could be eligible for a new life-extending combination therapy to treat rare forms of gastro-oesophageal cancer after NICE published final draft guidance today.

Nivolumab (Opdivo; Bristol Myers Squibb) given alongside chemotherapy has been recommended as an option for untreated HER2 negative, advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma if the tumours express PD-L1.

Read NICE press release

Michael Wonder

Posted by:

Michael Wonder